Least Burdensome Draft Guidance Would Unduly Increase RCTs - Medtronic
This article was originally published in The Gray Sheet
Executive Summary
FDA's draft guidance on least burdensome premarket requirements likely would increase above current levels the frequency at which randomized controlled trials (RCTs) are required to support premarket approval, leading to "significant over regulation," Medtronic maintains in comments to FDA.
You may also be interested in...
LBITF, FDA "Concept and Principles" Draft Attests Collaborative Effort
Reviewers of 510(k) premarket submissions should limit their analyses to claims "that present a major impact on the intended use of the device," according to principles set forth in a least burdensome industry task force (LBITF) and FDA draft document released for comment on FDA's website March 20.
LBITF, FDA "Concept and Principles" Draft Attests Collaborative Effort
Reviewers of 510(k) premarket submissions should limit their analyses to claims "that present a major impact on the intended use of the device," according to principles set forth in a least burdensome industry task force (LBITF) and FDA draft document released for comment on FDA's website March 20.
Post-Market Studies May Be "Least Burdensome" Alternative - Industry
FDA should consider postmarket controls for breakthrough devices as an alternative to randomized, controlled clinical studies as a "least burdensome" route to approval, a pan-industry task force suggests in Nov. 24 comments on FDA's draft guidance.